



Monte Carlo Patient QA Accuracy for Varian Halcyon launch at AAPM by IBA Dosimetry

New SciMoCa™ Monte Carlo patient QA now enables fast and efficient Quality Assurance accuracy for the Varian Halcyon™ in addition to all other major radiation therapy systems.

San Antonio, TX, USA, July 10th, 2019 – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy (PT) solutions and radiation therapy integrated quality assurance (QA), announces the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual AAPM meeting. The new release of SciMoCa provides the first and only worldwide commercial Monte Carlo Patient QA for the Varian Halcyon™ System. Healthcare professionals can now verify all Halcyon treatment plans independently, accurately, and with an automated and efficient workflow. The fast Monte Carlo dose calculation enables highly accurate results even for the most challenging cases like non-coplanar SBRT, and in particular for indications with tissue inhomogeneity like lung and head & neck treatments.

Monte Carlo is the gold standard for dose calculation accuracy in treatment planning. With SciMoCa, the accuracy of Monte Carlo is now available for independent secondary dose calculation and patient QA as well, allowing users to verify the most advanced treatment plans with an equally robust and fast QA solution. SciMoCa is used clinically for all standard Linear Accelerator types, for the Accuray® CyberKnife® and TomoTherapy®/Radixact, and is now also compatible with Varian Halcyon.

The high-quality beam models for SciMoCa are created linac-specific for customers applying dedicated processes, expert tools and experience. This unique process allows an independent verification of the commissioning data and the TPS model, providing an additional level of peace of mind about the accuracy of the machine and TPS commissioning. This is particularly valuable for pre-commissioned treatment machines like Halcyon.

“We are proud to introduce the first and only Monte Carlo patient QA solution for the Varian Halcyon™ at the AAPM 2019. This advancement to SciMoCa will enable customers to significantly

Press release | 10/07/2019

IBA | Dosimetry GmbH

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10
Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262
Managing Directors (Geschäftsführer): Olivier Legrain, Jean-Marc Bothy, Soumya Chandramouli
Dosimetry-info@iba-group.com | www.iba-dosimetry.com

**PROTECT +
ENHANCE +
SAVE LIVES**



save QA time whilst increasing the quality of patient treatment,” said Jean-Marc Bothy, President of IBA Dosimetry GmbH. “With SciMoCa’s workflow automation, calculation speed, and proven accuracy, we offer a real game changer in advanced 3D patient QA for the Halcyon™ and for all other major treatment systems.”

The SciMoCa software is manufactured by Radialogica LLC and globally distributed by IBA Dosimetry.

To find out more please visit iba-dosimetry.com

*** ends***

About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at iba-dosimetry.com

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at iba-worldwide.com

Media Contact: Ralf Schira, Director Global Marketing, IBA Dosimetry, ralf.schira@iba-group.com

Press release | 10/07/2019

2

IBA | Dosimetry GmbH

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10
Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262
Managing Directors (Geschäftsführer): Olivier Legrain, Jean-Marc Bothy, Soumya Chandramouli
Dosimetry-info@iba-group.com | www.iba-dosimetry.com

PROTECT +
ENHANCE +
SAVE LIVES